Under the collaboration, Metabolon will apply its platform to discover and validate targets, and identify novel pharmacodynamic biomarkers for translation into the clinic.
Metabolon has developed a proprietary analytical platform and software using metabolomics for biomarker discovery by measuring all of the biochemicals in a biological sample via its proprietary global processing method.
Through the generation and interpretation of data, the method allows a precise understanding of disease etiology and drug action, and advances personalized medicine, the company said.
Metabolon CEO John Ryals said the company believes that integrating metabolomic profiling into Takeda’s R&D programs may lead to novel therapies and informed decisions.